Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $8.6400 (-0.23%) ($8.5600 - $8.9700) on Mon. Oct. 28, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.81% (three month average) | RSI | 74 | Latest Price | $8.6400(-0.23%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.8% a day on average for past five trading days. | Weekly Trend | FOLD advances 4.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) XBI(56%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.405% in a week (0% probabilities). VIXM(-33%) VXX(-19%) TLT(-14%) TIP(-1%) UNG(-0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.405% (StdDev 2.81%) | Hourly BBV | 0 () | Intraday Trend | -0.5% | | | |
|
5 Day Moving Average | $8.48(1.89%) | 10 Day Moving Average | $8.35(3.47%) | 20 Day Moving Average | $8.14(6.14%) | To recent high | -33.2% | To recent low | 15.5% | Market Cap | $2.231b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |